Skip to content

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Hartmut Döhner, Elihu H. Estey, David J. Grimwade, Sergio Amadori, Frederick R. Appelbaum, Thomas Büchner, Hervé Dombret, Benjamin L. Ebert, Pierre Fenaux, Richard A. Larson, Ross L. Levine, Francesco Lo‐Coco, Tomoki Naoe, Dietger W. Niederwieser, Gert Jan Ossenkoppele, Miguel Ángel Sanz, Jorge Sierra, Martin S. Tallman, Hwei‐Fang Tien, Andrew H. Wei, Bob Löwenberg, Clara Derber Bloomfield

Blood · 2016 · 5,938 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Döhner, H., Estey, E. H., Grimwade, D. J., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., Levine, R. L., Lo‐Coco, F., Naoe, T., Niederwieser, D. W., Ossenkoppele, G. J., Sanz, M. Á., Sierra, J., Tallman, M. S., Tien, H., … Bloomfield, C. D. (2016). Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 129(4), 424–447. https://doi.org/10.1182/blood-2016-08-733196

In text: (Döhner et al., 2016)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.

  1. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia2016
  2. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF12010
  3. IDH1 and IDH2 Mutations in Gliomas2009
  4. Proposals for the Classification of the Acute Leukaemias F rench ‐A merican ‐B ritish (FAB) C o‐operative G roup1976
  5. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia2013

Metadata from OpenAlex (CC0). Citations are generated from the published record.